ROS1 abstracts at #WCLC19

Below are all the abstracts related to ROS1 NSCLC listed in the scientific program for the 2019 IASLC World Conference on Lung Cancer in Barcelona, Spain September 7-10.  While the times and locations of sessions may change, the numbers and names will not. 

ES14 – What First Line in Oncogene Addicted NSCLC

    • 15:15 – 16:45
    • 9/08/2019
    • Location: Vancouver (2003)
    • Type: Educational Session
    • Track: Targeted Therapy
    • Moderators: Dolores Isla, Jessica Menis

ES14.03 – First Line in ROS1 Translocated Patients
15:45 – 16:00 Presenting Author(s): Frances Shepherd

——————–
Sunday Sep 8 ePosters (Exhibit Hall 0800-1800)

EP1.09-05 – Correlation of ROS1 (D4D6) Immunohistochemistry with ROS1 FISH Analysis in Lung Adenocarcinoma: Is IHC a Reliable Screening Tool?Track: Pathology
Presenting Author(s): Shivani Sharma  |  Author(s): Aditi Dewan, Lata Kini, Mohit Bhardwaj, Shivmurti Kumar, Devender Sharma, Brijpal Singh Yadav, Rakesh Pandey, Kamakhya Gogai

EP1.14-33 – Intestinal Metastasis from Primary ROS1-Positive Lung Adenocarcinoma Patients Responding to Crizotinib
Track: Targeted Therapy
Presenting Author(s): Chunwei Xu  |  Author(s): Huafei Chen, Youcai Zhu, Xiaofeng Li, Lixin Wu, Kaiqi Du, Wenxian Wang, Meiyu Fang

EP1.14-45 – ROS1-ADGRG6: A Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib
Track: Targeted Therapy
08:00 – 08:00  |  Presenting Author(s): Chunwei Xu  |  Author(s): Xingliang Li, Shuguang Xu, Wenxian Wang, Junhui Ye, Youcai Zhu, Ting Ge, Meiyu Fang, Tangfeng Lv, Yong Song

———————————–
Sunday Sep 8 Poster Session (Exhibit Hall 0945-1800)

P1.01-56 – Increased ROS1 and RET Transcripts in Fusion-Negative NSCLC Patients
Track: Advanced NSCLC
09:45 – 09:45  |  Presenting Author(s): Noemi Reguart  |  Author(s): Cristina Aguado, Cristina Teixido, Ana Gimenez-Capitan, Elba Marin, Ana Peréz-Rosado, Carlos Cabrera, Ruth Román, Irene Moya, Santiago Viteri, Rafael Rosell, Miguel Angel Molina-Vila

P1.01-83 – Comparative Efficacy Analysis Between Entrectinib Trial and Crizotinib Real-World ROS1 Fusion-Positive (ROS1+) NSCLC Patients
Track: Advanced NSCLC
Presenting Author(s): Robert C. Doebele  |  Author(s): Laura Perez, Huong Trinh, Michael Martinec, Reynaldo Martina, Todd Riehl, Matthew G Krebs, Neal J. Meropol, Will Wong, Gracy Crane

P1.01-104 – Survivals in ROS1-Rearranged Advanced Non-Small-Cell Lung Cancer Treated with First-Line Crizotinib
Track: Advanced NSCLC
Presenting Author(s): Yu-Er Gao  |  Author(s): Chang Lu, Hua-Jun Chen, Zhen Wang, Bin-Chao Wang, Xu-Chao Zhang, Chong-Rui Xu, Yi-Long Wu, Jin-Ji Yang

P1.14-03 – Molecular Determinants for Lorlatinib Activity in ROS1 Positive NSCLC: Results of the Prospective PFROST Trial
Track: Targeted Therapy
Presenting Author(s): Lorenza Landi  |  Author(s): marcello Tiseo, Lukas C Heukamp, Roopika Menon, Gianluca Spitaleri, Diego Luigi Cortinovis, Angelo Delmonte, Domenico Galetta, Manolo D’Arcangelo, Federica D’Incà, Miriam Bertrand, Balázs Jóri, Angela Zacher, Cesare Gridelli, Silvia Novello, Rita Chiari, Claudio Verusio, Lucio Crino, Federico Cappuzzo

P1.14-12 – A Novel Activating MAP2K1 In-Frame Deletion Mediates Acquired Resistance to ROS1 TKIs in a Patient with ROS1 Fusion-Positive NSCLC
Track: Targeted Therapy
Presenting Author(s): Hiroki Sato  |  Author(s): Adam J Schoenfeld, Evan Siau, Ken Suzawa, Christine Yue, Michael Offin, Alexander Drilon, Monika A Davare, Gregory J Riely, Marc Ladanyi, Romel Somwar

P1.14-15 – Lorlatinib in ALK- or ROS1-Positive Non-Small Cell Lung Cancer Patients: Experience from an Early Access Program in Turkey
Track: Targeted Therapy
Presenting Author(s): Umut Demirci  |  Author(s): Saadettin Kilickap, Fatma Basal Bugdayci, Deniz Tural, Taner Korkmaz, Semra Paydas, Cengiz Yilmaz, Hande Turna, Ahmet Sezer, Havva Yesil Cinkir, Kerem Okutur, Mustafa Erman, Yesim Eralp, Devrim Cabuk, Abdurrahman Isikdogan, Ahmet Demirkazik, Aziz Karaoglu, Dogan Yazilitas, Filiz Cay Senler, Perran Fulden Yumuk, Hasan Senol Coskun, Ibrahim Yildiz, Ilhan Oztop, Ismail Beypinar, Kubra Aydin, Muhammed Ali Kaplan, Nezih Meydan, Omer Fatih Olmez, Ozgur Ozyilkan, Selcuk Seber, Cagatay Arslan, Mehmet Ali Nahit Sendur, Irfan Cicin

P1.14-29 – Disrupting the Paradigm: Partnering with Oncogene-Focused Patient Groups to Propel Research
Track: Targeted Therapy
Presenting Author(s): Janet Freeman-Daily  |  Author(s): Bonnie Addario, Colin Barton, Upal Basu Roy, Shelley B Blam, Ivy Elkins, Jill Feldman, Anita Figueras, Robert Hanlon, Marcia Karen Horn, Pasi A Jänne, Christine M Lovly, Amy Moore, Terry L Ng, Alicia Sable-Hunt, Sandra Shaw, Robert C. Doebele

P1.14-50 – A Phase 2 Trial of Cabozantinib in ROS1-Rearranged Lung Adenocarcinoma
Track: Targeted Therapy
Presenting Author(s): Robin Guo  |  Author(s): Isabel Preeshagul, Adam J Schoenfeld, Caroline G. McCarthy, Alex Makhnin, Andrew J. Plodkowski, Michelle S. Ginsberg, Monika A Davare, Lukas Delasos, Romel Somwar, Maria E. Arcila, Gregory J Riely, Natasha Rekhtman, Marc Ladanyi, Mark G Kris, Alexander Drilon

——————–
PC01 – Reinventing Clinical Trials


PC01.02 – Real World Research Groups – ROS1ders
11:15 – 11:30  |  Presenting Author(s): Merel Hennink

——————–
MA14 – The Adequate MTarget Is Still the Issue


MA14.02 – Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases
15:50 – 15:55  |  Presenting Author(s): Luis Paz-Ares  |  Author(s): Rafal Dziadziuszko, Alexander Drilon, Tom John, Matthew G Krebs, George Demetri, Alice T. Shaw, Salvatore Siena, Juergen Wolf, Anna F Farago, Brian Simmons, Chenglin Ye, Xinhui Huang, Robert C. Doebele

——————–
MA22 – Partnering with Patients to Understand Stigma, Disparities and Values Leading to Improved Lung Cancer Care


MA22.03 – The ROS1ders: Partnering to Drive Research and Improve Outcomes in ROS1+ Cancers
15:55 – 16:00  |  Presenting Author(s): Janet Freeman-Daily  |  Author(s): Lisa Goldman, Lysa Buonnano, Tori Tomalia

——————–
Monday Sep 9 Poster Session (Exhibit Hall 1015-1815)

P2.03-07 – Frequency of Driver Genes (EGFR, KRAS, BRAF, ALK, RET and ROS1) Alterations in Brazilian Patients with Lung Adenocarcinoma
Track: Biology
Presenting Author(s): Letícia Ferro Leal  |  Author(s): Lazaro Antonio Campanha Novaes, Rodrigo de Oliveira Cavagna, Flávia Escremim De Paula, Pedro De Marchi, Maicon Fernando Zanon Da Silva, Adriane Feijó Evangelista, Luciane Sussuchi Da Silva, Eduardo Caetano Albino Da Silva, Rui Manuel Reis

P2.03-27 – Discovery of WNK1-ROS1 Fusion in a Lung Adenocarcinoma Patient and the Precise Guidance for Targeted Therapies
Track: Biology
Presenting Author(s): Rui Lin  |  Author(s): Tianfeng Liu, Yutao Liu, Nan Li, YUe Pu, Tao Wang

P2.09-27 – Correlation Between Different ROS1 Clones (SP384 & D4D6) and Consistency with ROS1 Fluorescence in Situ Hybridization (FISH) Results
Track: Pathology
Presenting Author(s): Büge Aysim Öz  |  Author(s): Onur Dulger, Şebnem Batur

P2.09-33 – Prevalence of ROS1 (SP384)-Reactive Type II Pneumocyte Staining in Lung Tissue
Track: Pathology
Presenting Author(s): Ina Menzl  |  Author(s): Catherine H Le, Richard S.P. Huang, Tyler Foutch, Charmi Patel, Amy E. Hanlon Newell, Greg Pate

P2.14-09 – Concurrent TP53 Mutation Adversely Impact the Efficacy of Crizotinib in ROS1-Rearranged Lung Cancer Patients

Track: Targeted Therapy
Presenting Author(s): Gen Lin  |  Author(s): Huamin Xu, Jun Zhao, Jinliang Kong, Xinghao Ai, Fenglei Yu, Kaiqi Du, Lingjun Zhu, Lin Li, Hongxia Ma, Qiaoli Wang, Huanhuan Xiong, Rongrong Chen, Xuefeng Xia

P2.14-46 – Treatment Observations and Clinical Experience with Lorlatinib in Pretreated ALK and ROS1 Rearranged NSCLC Patients
Track: Targeted Therapy
Presenting Author(s): Maximilian J. Hochmair  |  Author(s): Christoph Weinlinger, Hannah Fabikan, Oliver Illini, Dagmar Krenbek, Ulrike Setinek, Stefan Watzka, Renate Koger, Michael Meilinger, Gudrun Absenger, Michael Wanke, Christoph Semmelweis, Markus Rauter, Arschang Valipour

P2.14-61 – Acquired Resistance to Entrectinib Associated with Activation of RAS Signaling Pathway in ROS1-Rearranged Non-Small Cell Lung Cancer
Track: Targeted Therapy
Presenting Author(s): Bo Mi Ku  |  Author(s): Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn

P2.14-69 – Lorlatinib Rescue Therapy for Life Threatening CNS Disease in Crizotinib-Resistant ROS1-Positive Non–Small Cell Lung Cancer (NSCLC)
Track: Targeted Therapy
Presenting Author(s): Aaron John Franke  |  Author(s): Viswam S Nair, Michael Shafique, Sepideh Mokhtari

P2.16-05 – Population-Based ROS1 Testing in Lung Cancer: Creating Opportunity in a Publicly Funded System
Track: Treatment in the Real World – Support, Survivorship, Systems Research
Presenting Author(s): Maisam Makarem  |  Author(s): Doreen Ezeife, Adam C Smith, Jennifer H Law, Ming Sound Tsao, Natasha B Leighl

Published by

Gray Connections

I was diagnosed with non-small cell lung cancer in May 2011. The cancer became metastatic in October 2011. No, I never smoked anything (except a salmon). I've had no evidence of disease since January 2013 thanks to precision medicine, clinical trials, and other patients. ANYONE can get lung cancer. Using my engineering degrees (MIT SBME 1978, Caltech Aeronautics MS 1984 and ENGR 1986), I enjoyed a 20-year career in aerospace systems engineering as a technical translator of sorts: I researched a scientific or engineering subject and helped others understand how this new gizmo could benefit them. In the time I have left, I want to use my skills to help others who have lung cancer, and increase the visibility and knowledge of lung cancer among those who don't. I also study brain research, enjoy traveling, write science fiction, and geek out about all sorts of science stuff.

One thought on “ROS1 abstracts at #WCLC19”

Comments are closed.